Both PPARγ and SREBP-1c are upregulated in obese patients with NAFLD [37]; they can both self-activate directly or indirectly [38,39,40,41] and augment each other [27,28,42,43]. Here, PPARG is linked to metabolic dysfunction-associated steatotic liver disease.